FDA Enforcement Discretion for Compounded GLP-1s

What ended, what didn't, and which rule your prescription is actually on

By The RX Index Editorial Team · Last verified: September 3, 2026 · Next review trigger: an FDA final determination, a new shortage-list change, or further court action

How we made this page: we read the dates off the FDA's own compounding policy page, pulled the shortage status package by package from the FDA's shortage database, opened the individual warning letters we cite, checked the two federal appeals, and verified each price on the provider or manufacturer's own site. Nothing here came from a press summary. Where we couldn't confirm something, we say so instead of guessing.

---

The short answer

FDA enforcement discretion for compounded GLP-1s did not end. It shrank.

The big one is gone. After the FDA resolved the tirzepatide and semaglutide shortages, it closed the temporary wind-down policies that gave compounders time to stop making, shipping, or dispensing affected copies. The last piece expired May 22, 2025.

But a smaller one is still in force. The FDA has said it does not intend to act under one part of the 503A copy rule when a compounder fills four or fewer prescriptions of a given compounded drug product in a calendar month. That's a policy aimed at compounders, not a shopping permission slip — and we'll explain exactly why that distinction matters in a minute.

What changes the answer for you: which drug you're on, which pharmacy made it, whether it operates under 503A or 503B, what was changed, and what your prescriber wrote in your record.

---

Which of the six rules people actually mean

Six different rules, policies, and news stories get blended together under the words "enforcement discretion." They are not the same thing.

Sources: FDA compounding policy page, FDA Drug Shortages Database, and FDA Pharmacy Compounding Advisory Committee materials. Verified September 3, 2026.

---

This page is for you if

• Your compounded semaglutide or tirzepatide refill changed, stopped, or got a nervous-sounding email attached to it
• You saw the word "ban" in a headline and want to know the actual rule
• A seller told you B12, a custom dose, or "it's patient-specific" makes their product fine
• You run a pharmacy, clinic, or telehealth program and need the exact dates with citations

This page is not for you if

• You've already decided to switch and just want prices. Go to GLP-1 cost without insurance instead.
• You want your state's rules. Federal rules are only half the picture. Use the NABP board directory to reach your state's pharmacy regulator and license lookup.
• You want the warning letters themselves. They live in our enforcement tracker.
• You want us to tell you your specific prescription is legal. We can't. Nobody writing an article can. We'll explain why, and give you the questions that get you an actual answer.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

---

What people are actually trying to solve

The same three fears keep driving this search:

• Your refill still shipped after headlines said the shortage route had ended
• A seller says B12, a custom dose, or the words "patient-specific" make everything fine
• You're thinking about stockpiling because you don't know what happens next

If any of those sound like the inside of your head right now, you're in the right place. Nobody has explained this well, which is most of the problem.

---

What does "enforcement discretion" actually mean?

Enforcement discretion is the FDA saying, out loud and in writing, that it doesn't plan to take action against a certain violation under stated facts or for a stated stretch of time. It is not approval. It is not a license. It's a stated intention, and the FDA can narrow it or drop it. That's exactly what happened here.

Think of the post-shortage wind-down like a police department announcing it won't ticket one stated violation until a set date. The law did not turn the product into an approved drug. When the wind-down ended, normal enforcement returned.

That's what tripped up a whole industry. While a drug was on the FDA shortage list, federal law itself changed how the copy restrictions applied. After the shortage basis ended, the FDA gave wind-down periods as enforcement discretion. A lot of people — including some who should have known better — treated that as approval. It wasn't.

What enforcement discretion never meant

Let's clear these out now, because half the confusion on this topic starts here:

• It did not make any compounded product FDA-approved
• It did not make it a generic
• It did not mean the FDA approved the telehealth company or the pharmacy
• It did not cancel state pharmacy rules
• It did not promise the product was strong enough, pure enough, or safe

The FDA has been blunt about the last point. In its June 8, 2026 Ready Med warning letter, the agency said compounded drug products "have not been evaluated by FDA for safety, effectiveness, or quality before marketing." That's the baseline. It was true during the shortage and it's true today.

Two phrases to keep straight

A company that blurs those two is telling you something about itself.

---

Did FDA enforcement discretion for compounded GLP-1s end?

Partly. The post-shortage enforcement-discretion periods ended in 2025 — March 5 for 503A tirzepatide, March 19 for 503B tirzepatide, April 24 for 503A semaglutide, and May 22 for 503B semaglutide. A separate, much narrower 503A non-enforcement policy is still in place, and the FDA restated it on April 1, 2026.

Here's the part almost every article gets wrong.

Search this topic and you'll read "enforcement discretion has ended" on page after page. That sentence is incomplete, and the incompleteness is why you're confused.

What ended: the post-shortage wind-down policy. While semaglutide and tirzepatide were in shortage, the shortage-list rules changed the copy analysis. Once the FDA declared the shortages resolved, that basis disappeared, and the agency gave affected compounders a wind-down window. Those windows are closed.

What didn't end: on its current compounding policy page, the FDA states that at this time it does not intend to take action under the 503A "regularly or in inordinate amounts" condition if that compounder fills four or fewer prescriptions of that compounded drug product in a calendar month.

That's enforcement discretion. It's current. It isn't specific to GLP-1s.

Now read this part carefully

Four or fewer is not a loophole, and it is not for you.

It's a policy aimed at 503A compounders about one specific condition in the law — the "regularly or in inordinate amounts" test. It doesn't mean the product is approved. It doesn't mean every other 503A requirement is satisfied. And it doesn't mean a seller can point at it and keep shipping thousands of orders.

Do the math. Four prescriptions of one compounded drug product, per compounder, per calendar month. That's a small-volume number for that product. A national telehealth brand filling thousands of orders cannot point to this four-per-product, per-compounder policy as a blanket explanation for those thousands.

So if a company tells you it's "operating under FDA enforcement discretion," the honest follow-up is: which policy, which legal condition, and how many prescriptions of this exact compounded drug product do you fill each month? A real answer takes about four seconds. A dodge tells you what you need to know.

---

Exactly when did FDA enforcement discretion end for each GLP-1?

There were four drug-and-compounder wind-down deadlines, not one, plus an earlier tirzepatide reevaluation policy and the standing four-or-fewer policy. Two operative dates moved because the FDA tied them to court rulings — which is why websites disagree about this.

The October 2024 tirzepatide reevaluation policy was not a clean fifth deadline. In an October 17 letter, the FDA tied that non-enforcement period to its new shortage decision and, if a preliminary-injunction motion was filed, to the court's ruling. Later FDA updates set the final 503A and 503B dates below.

This is the table nobody built. We built it from the FDA's own dated entries.

The enforcement discretion ledger

The FDA's October 17, 2024 letter described the reevaluation policy and its court-linked duration. The later wind-down rows and the four-or-fewer policy come from "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize". Verified September 3, 2026.

Why every website gives you a different date

Not sloppiness. There's an actual reason, and once you see it, the contradictions stop.

The FDA tied all four 503A and 503B wind-down deadlines to the relevant court ruling. Only the two 503A dates moved, because the court rulings came after the printed 503A dates but before the printed 503B dates. So there are two real numbers for those two events, and different writers grabbed different ones.

If you've been going back and forth between two articles wondering which one is lying — neither has to be. They may have picked different stages of the same FDA timeline.

Not sure what path fits now? The RX Index's Find My GLP-1 Path tool asks up to nine plain-English questions about your medication preference, health flags, payment path, state, and timing. Free, no signup. It gives you a route to discuss with a licensed clinician; it does not decide whether your prescription is legal.

---

Is compounded semaglutide or tirzepatide legal in 2026?

Federal law still allows drug compounding when every condition under 503A or 503B is met. What's no longer permitted under current facts is routine, mass-market copying of semaglutide or tirzepatide through the old shortage and wind-down paths. Narrow lanes remain, and they depend on the compounder, the formula, the volume, and the records — not on a marketing line.

Here's the honest version, and we're not going to dress it up.

We can't hand you a way to keep buying cheap compounded semaglutide like it's 2024. That door has closed for most people, and any seller promising otherwise should make you suspicious rather than relieved.

The part that actually matters: FDA-approved options got dramatically cheaper while you weren't looking, and there's a real path to keep your progress. We'll get there.

Which bucket is your prescription in?

Most compounded semaglutide or tirzepatide offers land in one of five federal buckets. Only two are plausible 503A lanes under current facts, and neither is automatic permission.

On bucket 5, the FDA draws two different lines. It says retatrutide and cagrilintide cannot be used in compounding under federal law and haven't been found safe and effective for any condition. For the salt forms — semaglutide sodium and semaglutide acetate — the agency says they are different active ingredients than the ones in approved semaglutide products and that it isn't aware of any lawful basis for using them in compounding.

Why we won't tell you your prescription is legal

Because it depends on things we can't see from here: which company actually made the drug, whether they're operating under 503A or 503B, what your prescription says, what your prescriber documented, the formula, the volume, your state's rules, and how the product was marketed.

Any website that tells you your specific prescription is fine is either guessing or selling.

That limitation is exactly why the next few sections matter. If a provider can't answer the questions below clearly, you've learned something important — before you put anything in your body.

---

Does this apply to my pharmacy? (503A and 503B in plain English)

The rules split by what kind of compounder makes your medicine. A 503A pharmacy or physician compounds for an identified patient under a prescription-based model. A 503B outsourcing facility may make larger batches under federal registration, current good manufacturing practice rules, and a different set of copy and bulk-ingredient rules. They got different deadlines and they live under different rules today.

The 503B Bulks List is the FDA's list of bulk drug substances outsourcing facilities may use when the FDA finds a clinical need. A separate door exists when the drug is on the FDA shortage list at the time of compounding, distribution, and dispensing.

On its current policy page, the FDA states plainly that tirzepatide and semaglutide do not appear on the 503B Bulks List or on the FDA's drug shortage list. Both current bulk-ingredient doors are closed for those two drugs.

The May 2026 503B proposal to exclude semaglutide, tirzepatide, and liraglutide is not itself a final determination. The comment period was extended to July 30, 2026; as of this verification, the official FDA and Federal Register sources reviewed here do not show a final rule replacing that proposal. The law keeps the Bulks List route and the shortage-list route separate.

What the Fifth Circuit changed

The two related appeals are no longer pending at the circuit level. On August 27, 2026, the Fifth Circuit affirmed the judgment for FDA in Outsourcing Facilities Association v. FDA, No. 25-10600, the tirzepatide case. The court also issued a revised opinion in the semaglutide appeal, No. 25-10758, filed September 1, 2026, affirming the judgment for FDA. Those decisions uphold the FDA shortage-delisting actions; they do not make compounded semaglutide or tirzepatide FDA-approved and do not eliminate the separate 503A or 503B statutory requirements.

Sources: Fifth Circuit No. 25-10600 opinion, filed August 27, 2026 and revised No. 25-10758 opinion, filed September 1, 2026.

The different GLP-1 still in current shortage records

Here's a detail most consumer pages miss.

Semaglutide and tirzepatide are off the shortage list. Liraglutide injection is still in the FDA's current shortage data, with an initial posting date of July 18, 2023. Because one 503B route turns on shortage-list status, that isn't trivia. It can change the analysis for liraglutide drug products. It does not make every compounded liraglutide product lawful, and it does not reopen semaglutide or tirzepatide.

Here's exactly where liraglutide stood, package by package, when we pulled the FDA's shortage data on August 20, 2026:

Two things worth noticing. The estimated recovery date on that Meitheal package had already come and gone, and the record hadn't been refreshed since June 1. And the FDA's "last updated" date is different for every company and package inside one drug's record — so there's no single honest "as of" date for every liraglutide package. Most trackers don't mention that.

To be clear about what this is and isn't: we're reporting the rule and the database record. This is not a consumer route to compounded weight-loss medication, and we're not presenting it as one. Liraglutide is a different drug with different dosing, evidence, and supply facts. If someone tries to sell you a "loophole" built on this paragraph, that's them, not us.

Why "made by a licensed pharmacy" isn't enough

It sounds reassuring. It tells you almost nothing.

You want to know which pharmacy, whether it's 503A or 503B, what exact ingredient form it used, and what basis applies to your prescription. A trustworthy provider answers without flinching.

And registering with the FDA proves less than people think. In its June 2026 Ready Med warning letter, the FDA said registration does not equal FDA approval or licensure of the facility or its compounded products. The agency went further: there is no such thing as an "FDA-approved" or "FDA-licensed" pharmacy. That designation doesn't exist. Anyone claiming it is describing something that isn't real.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a treatment-access route based on those facts before you choose.

---

What does "essentially a copy" mean?

Under the FDA's 503A guidance, a compounded product may count as essentially a copy when it uses the same active ingredient as an available approved drug, at the same, similar, or easily swapped strength, and can be taken the same way. A prescriber's documented finding that a change produces a significant difference for one identified patient can change that 503A analysis.

Break it into four pieces and it stops being intimidating:

1. Same active ingredient as a drug you can already buy
2. Same, similar, or easily swapped strength
3. Same way of taking it — the FDA calls this the route of administration
4. That drug is commercially available right now

Hit all four and you're looking at a 503A copy under the FDA's framework. Unless — and this is the whole ballgame — a prescriber determines and documents that a change produces a significant difference for you as an identified individual.

Note who makes that call. Not the website. Not the marketing team. Not you. The prescriber, and it has to be written down.

Do not carry that answer over to 503B. The 503B wording is different. An identical or nearly identical product can't be saved by a patient-specific clinical-difference note, and the bulk-ingredient rule still has to be satisfied. A seller that answers a 503B question with a 503A slogan hasn't answered your question.

Questions to ask about your documented difference

If a provider is keeping you on a compounded GLP-1, these six get you a real answer:

1. What specific thing about the approved product doesn't meet my medical need?
2. What exactly was changed in my prescription?
3. Where is that decision documented?
4. Is that difference significant for me, or only administrative?
5. Which pharmacy is filling it?
6. Would an FDA-approved version meet the same need?

Six questions. If the answers get vague around number three, you have your answer.

---

Does adding B12 or changing my dose change the FDA's answer?

Not by itself. The FDA has said directly that a semaglutide-plus-B12 product can still count as essentially a copy, and it put a number on it: when the amount of each ingredient lands within 10% of the strength of the respective commercially available product, and it's taken the same way, that's a copy under its 503A example. A different dose or form changes the facts — it doesn't erase the requirements.

The B12 thing

"Now with B12!" is not a legal argument. Read it as a claim to check.

The FDA published its own worked example. It looks at whether the two products are taken the same way — an injection compared to an injection — and whether the amounts of semaglutide and vitamin B12 sit within 10% of the strengths of the respective commercially available products. Meet those conditions and you're still looking at a copy, B12 or no B12.

There's a second reason to slow down here, and it isn't the copy rule. In a 2026 peer-reviewed paper, authors affiliated with Eli Lilly — tirzepatide's maker — reported a reaction product or impurity in mass-compounded tirzepatide/B12 samples. The paper said the clinical effects were unknown. Nobody is claiming that's proven harmful. Nobody can claim it's proven safe either. That's the honest state of it.

Custom doses

Adjusting a dose genuinely helps some patients. That's real medicine.

But a different number on a label, applied to everybody who signs up, is a marketing template — not a documented patient-specific difference. The test is whether a prescriber identified something specific about you, changed the product for that reason, and wrote it down.

Drops, tablets, lozenges, and sprays

A different form may change part of the copy analysis. It doesn't make the product approved, and it doesn't prove it works.

FDA-approved oral GLP-1 products now exist. A compounded drop, lozenge, spray, or under-the-tongue product is not the same thing as an FDA-approved tablet, and the FDA hasn't pre-reviewed that exact compounded form for absorption, dose, safety, effectiveness, or quality. Run any of them past a licensed clinician or pharmacist before you use them.

Claim decoder

---

What is the FDA actually enforcing right now?

The FDA's recent compounded GLP-1 actions have focused on marketing that presents compounded products as the same as approved drugs, labeling that hides or confuses who made the medicine, and claims of "FDA-licensed" status that doesn't exist. As of May 31, 2026, the agency had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide.

Rather than describe the enforcement in the abstract, we opened one letter and took it apart. It's the clearest map of what draws FDA attention that we've found.

One letter, three claims, three problems

On June 8, 2026, the FDA sent a warning letter to a Clearwater, Florida telehealth company called Ready Med (reference MARCS-CMS 730317). The agency had reviewed the company's website in May 2026. Here's what it objected to, item by item:

Source: FDA Warning Letter to Ready Med, MARCS-CMS 730317, June 8, 2026. Read in full and verified August 20, 2026.

The letter warned that failure to fix the violations could lead to legal action, including seizure and injunction.

Why this is useful to you: those three things are visible from your couch. Open the website you're buying from. Does the telehealth brand put its name on a vial in a way that makes it look like the manufacturer? Does the copy say "same active ingredient" in a way that blurs the compound with an approved drug? Does it claim an FDA license? If yes, you're looking at the same kinds of claims the FDA already put in a warning letter.

The FDA's March 3, 2026 sweep sent warning letters to 30 telehealth companies over false or misleading compounded GLP-1 marketing claims.

The quality side, and how to read it fairly

Marketing isn't the only issue. In a letter dated January 16, 2026, the FDA documented findings at Boothwyn Pharmacy, a 503A pharmacy in Pennsylvania: a tirzepatide lot that failed a sterility test, and a semaglutide sample tested at about 79.9% of its labeled strength.

Here's the part most pages skip. A state license or FDA registration isn't a batch test. It tells you something about legal status or registration. It doesn't prove every lot is sterile or at the labeled strength.

And here's the fairness note: that's evidence about one inspected pharmacy and specific samples. It is not a failure rate for the whole category, and we're not going to pretend it is.

How to read the adverse event numbers

As of May 31, 2026: 990 reports for compounded semaglutide, more than 730 for compounded tirzepatide.

Three honest caveats:

• The FDA says many of these reports look similar to side effects seen with the approved versions
• A report doesn't prove the drug caused the problem
• The real number is probably higher. The FDA states that federal law doesn't require state-licensed pharmacies that aren't outsourcing facilities to report adverse events at all

That last one isn't a scare tactic. It's a structural gap in what anyone can know, and you deserve to know it exists.

One specific problem the FDA has flagged hard? Dosing errors. Compounded GLP-1s often ship in multi-dose vials where you measure your own dose. The agency has received reports of people measuring wrong — some serious enough to require hospitalization — and of clinicians miscalculating doses.

---

What's still undecided?

One federal item remains open at this verification. The FDA has proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List, and the comment period closed July 30, 2026. The related Fifth Circuit appeals have now been decided: No. 25-10600 was affirmed on August 27, 2026, and revised opinion No. 25-10758 was filed September 1, 2026.

PROPOSED — NOT FINAL. We're labeling that loudly because a lot of coverage has flattened this proposal into "the FDA banned it." It didn't. The FDA proposed not to include three bulk substances on one list, said its preliminary analysis didn't identify a clinical need, and opened comments. The comment period is over, but as of this verification the official sources reviewed here still do not show a final determination replacing the proposal.

One detail from the proposal that matters for anyone hoping affordability wins the argument: for the 503B Bulks List analysis, the FDA doesn't treat cost, convenience, or supply problems such as backorders as establishing "clinical need." If the theory is "compounded is cheaper, so there's a need," that isn't the test the agency is applying. The proposal also says the shortage-list route is separate.

Our method, so you can judge it: we checked the FDA's policy page, the Federal Register proposal and extension, the FDA's 503B Bulks List materials, and the official Fifth Circuit opinions on September 3, 2026. We found the proposal, the closed deadline, and the two appellate affirmances. We did not find a final Federal Register determination replacing the proposal. Absence of a finding isn't the same as certainty, so we're telling you what we searched and what we found rather than declaring the outcome.

---

Didn't the FDA just loosen the rules on peptides?

No GLP-1 rule changed. The FDA's Pharmacy Compounding Advisory Committee met July 23–24, 2026 to discuss seven different peptide-related bulk substances for the 503A Bulks List. Advisory committee work is not FDA approval or permission. Semaglutide and tirzepatide weren't on the agenda.

This section exists because "FDA," "enforcement discretion," and "compounding" are all over the news right now for a reason that has nothing to do with your prescription — and that's confusing people who search this topic.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157-related substances, KPV-related substances, TB-500-related substances, MOTS-c-related substances, emideltide-related substances, Semax-related substances, and Epitalon-related substances.

Two things to hold onto:

An advisory committee meeting is not permission. The committee advises. The FDA decides through the required process. Anyone selling a substance as FDA-permitted based only on a committee meeting is ahead of the facts.

Semaglutide and tirzepatide weren't on the agenda. Different substances, different list, different question.

Nothing about that July meeting changed the status of your compounded semaglutide or tirzepatide prescription.

---

Am I in trouble for taking a compounded GLP-1?

No — the FDA actions discussed here target companies, not patients. The warning letters we reviewed went to companies and didn't impose a patient penalty. What deserves your attention is what happens next — not what already happened.

We're putting this in its own section because it's the fear underneath a lot of the searching, and nobody says it plainly.

You followed a prescriber's instructions. You paid a company that presented itself as legitimate. We checked the FDA's March 3 sweep and the two individual warning letters analyzed on this page. Every named recipient was a company or pharmacy, not a patient.

If you still have doses in your fridge

Don't throw out medication because of a webpage. Don't stop, restart, ration, or change your dose because of one either.

Call your prescriber or dispensing pharmacy. Ask what they want you to do. A website isn't in a position to weigh anything else in your chart.

One thing the FDA is direct about: don't use any injectable GLP-1 that arrived warm or with insufficient refrigeration. Contact the pharmacy and your prescriber instead. The agency has received complaints about products arriving warm.

---

My compounded GLP-1 refill just stopped. What do I do?

Don't panic-buy from a site you found this morning. That's how people end up with salt forms, fake labels, and dosing errors. Take four steps instead — and don't change your dose on your own while you sort it out.

Step 1: Write down what you're actually on

Before you talk to anyone: the exact medication name, the dose in milligrams, the concentration, the pharmacy's name, your prescriber's name, the date of your last dose, and any side effects. Whoever helps you next needs all of it.

If you can't find a pharmacy name anywhere on the vial, the label, or the paperwork — that's information too.

Step 2: Ask why it stopped

"Was my refill stopped because of the FDA compounding rules, a pharmacy policy, a state law, my eligibility, or a supply issue — and is there anything I can do?"

Those five reasons lead to five completely different next steps. Guessing wastes weeks.

Step 3: Ask which lane you're in

"Is there a documented, patient-specific reason this compounded version is needed for me, what exactly was changed, and should I move to an FDA-approved option?"

A confident, specific answer may point to the 503A patient-specific lane. It doesn't prove every federal and state condition is met. A vague answer is your answer.

Step 4: Don't stockpile

We get the impulse. But stockpiling creates real problems: beyond-use dates, storage you can't control, a dose that may change, duplicate prescriptions, no clinician watching, and money spent on medication you might not end up using.

If you're taking a GLP-1 for type 2 diabetes: don't make any change based on an article. Contact whoever manages your blood sugar. That's a different risk calculation and it needs a person who knows your numbers.

---

What are my legal options, and what do they cost?

For most people whose routine compounded refill stopped, the realistic next comparison is an FDA-approved medication. The price picture changed more in the last year than most people realize. On August 20, 2026, self-pay programs started at $149 a month for certain oral starting doses and $299 for a 2.5 mg Zepbound KwikPen or four-vial month. Every number has dose, eligibility, and timing rules.

That's the mental trap. People freeze because they're measuring an old compounded price against a four-figure list price. List price is real, but it isn't the only cash-pay number anymore.

The honest comparison is your old compounded price against today's dose-specific cash-pay programs. Yes, an approved drug may still cost more than compounded did. But the product is FDA-approved, its labeled dose and presentation have been FDA-reviewed, and the source is easier to verify.

Verified price snapshot: August 20, 2026

Provider-stated versus independently verified

If your only reason was price

Read that again, because it's most people. If price was the only thing keeping you on a compounded product, the math that made that decision for you has changed underneath you.

Before you pay a membership, check whether your current prescriber can send an approved prescription straight to NovoCare or LillyDirect. That route skips a separate telehealth membership.

One honest caveat before we point you anywhere: medication pricing in this category moves constantly, offers expire, and your dose can change the price. Anything you see above or below should be confirmed on the provider or manufacturer's own site before you spend money. We date-stamp everything for exactly this reason.

Where a telehealth provider fits

If you'd rather not coordinate the prescription, the pricing, and the insurance paperwork yourself, an online provider handles it.

For the FDA-approved path, Ro is the one we'd point most people to first when they want clinical care and insurance help. Its Ro Body membership runs $39 for the first month, then $149/month — or as low as $74/month if you prepay for a year. Ro's own pricing page states that the $39 is refunded if you're not eligible for GLP-1 treatment. Medication is billed separately.

It also runs a free insurance coverage checker. Useful detail most reviews skip: that checker covers the Ozempic pen, Wegovy pen, and Zepbound autoinjector pen. It doesn't currently check Zepbound KwikPen, Foundayo, or the Wegovy pill.

The damaging admission, because you've earned one:

Ro is NOT the cheapest way to get an FDA-approved GLP-1. The membership fee sits on top of the medication, and the medication is billed separately. If rock-bottom price is your only goal and you already have a prescriber who'll write the script, buying direct from the manufacturer — LillyDirect or NovoCare — skips the membership entirely, and you should do that instead. But because Ro charges for care, it provides care: a clinician managing your dose, ongoing support, and an insurance team that handles benefits checks and prior-authorization paperwork for eligible plans. If you're stepping off a compounded dose and can't afford a gap in treatment, or if your plan might cover this and you don't want to spend three weeks on hold finding out, that's the part worth paying for.

Government-plan correction: Ro says people with Medicare, a Medicare supplement, or TRICARE may still qualify for certain cash-pay options through Ro Body. Its insurance concierge doesn't coordinate those government benefits. Federal Employee Health Benefits members can use the concierge. Ro says Medicaid and some other government-funded plans aren't eligible for treatment on Ro.

If you have Medicare Part D and need a weight-management GLP-1, check the Medicare GLP-1 Bridge before paying full cash price. Eligible members pay a $50 copay, but not everyone qualifies.

→ Check your GLP-1 coverage free with Ro's insurance checker (sponsored affiliate link, opens in a new tab)

A few questions, no commitment. Find out where you stand before you decide anything. The checker covers only the three pens named above and doesn't guarantee coverage.

Want to choose your own prescriber, or compare self-pay prices first? Sesame Care (sponsored affiliate link, opens in a new tab) offers provider choice, and Sesame advertises Costco-member pricing on some FDA-approved weight-management services. Reasonable second stop if Ro isn't your fit. Confirm the visit and medication price before you buy.

Ro membership pricing verified at ro.co on August 20, 2026. Medication prices are billed separately and change frequently — confirm at checkout.

If a prescriber documented a real reason for you

A patient-specific 503A analysis may apply. That doesn't prove the lane is open by itself. Two things to do: get the documented difference in writing, and verify the pharmacy behind your medication. Start with the NABP board directory to reach the right state license lookup, then search the exact pharmacy name and address on your label.

We're deliberately not sending you to a compounded seller from this page. On a page explaining that the mass-copy basis is gone, that would be us arguing against ourselves.

If you bought from an overseas or research-chemical seller

No links in this section. On purpose.

The FDA has warned companies selling unapproved products containing semaglutide, tirzepatide, or retatrutide labeled "for research purposes" or "not for human consumption" — while shipping them to consumers with dosing instructions. The agency's position is that these are of unknown quality and may be harmful.

If you've used one and you're having symptoms, talk to a clinician. You can report a product problem or adverse event to the FDA through its MedWatch program. Reporting it helps the FDA investigate.

---

How do I check a provider before my next refill?

Identify the prescriber, the actual dispensing pharmacy, whether it operates under 503A or 503B, and the current basis for the product. Walk away when no prescription is required, the pharmacy is hidden, or the seller calls the product a generic or an equivalent of an approved drug.

Seven questions to send before you pay

Copy and paste these. A legitimate provider answers all seven without a fight:

1. What is the full legal name and address of the pharmacy that will fill this?
2. Is it a 503A pharmacy or a 503B outsourcing facility?
3. Is it licensed to ship to my state?
4. What exact formulation and ingredient form will be on my label?
5. If it's 503A, what significant difference did my prescriber document for me? If it's 503B, which bulk-ingredient and copy rules does it rely on?
6. Who answers my questions after the medication arrives?
7. What happens if it shows up warm, damaged, or different from what I ordered?

Red flags the FDA itself has named

Run your situation through Find My Path

The RX Index's Find My GLP-1 Path tool asks up to nine short questions about medication preference, health flags, payment path, state, and timing.

You get a plain-English treatment and access route to discuss with a licensed clinician. It is free and doesn't require signup.

One thing it will never do: tell you your prescription is legal, tell you a provider is compliant, prescribe medication, or guarantee coverage. It can't, and neither can anyone else without the records that matter.

→ Find my GLP-1 path — free, up to 9 questions

---

What this page can't tell you

Straight answer: nothing here tells you whether your pharmacy is following the rules.

The FDA doesn't publish a list of compliant compounders. There's no public database of who fills four or fewer prescriptions a month. We can tell you which rule applies to which situation. We can't verify any individual seller for you, and anybody who says they can is guessing.

Here's what you can do. Use your state's pharmacy-license lookup. The NABP board directory links to the pharmacy regulator for each U.S. jurisdiction. That search can tell you whether the named pharmacy exists and is licensed where it says it is. It can't prove every prescription or batch is compliant — which is why the questions above still matter.

---

Frequently asked questions

Is FDA enforcement discretion the same as FDA approval? No. Approval means the FDA reviewed a specific finished product for safety, effectiveness, quality, and manufacturing before approval. Enforcement discretion means the FDA didn't pre-approve that exact compounded product and is stating that it doesn't intend to act under a specific legal condition. A compounded finished product isn't FDA-approved.

Did the FDA ban compounded GLP-1s? No single FDA action banned every compounded semaglutide or tirzepatide prescription. What ended was the shortage and wind-down basis for routine, mass-market copies. A narrow 503A patient-by-patient lane can still exist when a prescriber documents a significant difference and every other condition is met.

When exactly did enforcement discretion end for compounded tirzepatide? March 5, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. You'll also see February 18, 2025 — that was the date the FDA originally printed, before a court decision extended it to March 5.

When did it end for compounded semaglutide? April 24, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. The FDA originally printed April 22, but a court ruling on April 24 controlled.

Can a 503A pharmacy still compound semaglutide in 2026? In narrow circumstances. The prescription must be for an identified patient, it can't be essentially a copy of an available approved drug unless a prescriber has documented that a change produces a significant difference for that patient, and all the other 503A conditions still apply. Lower price alone doesn't make the product different.

What is the four-prescription rule? The FDA has stated that at this time it doesn't intend to take action under the 503A "regularly or in inordinate amounts" condition when a compounder fills four or fewer prescriptions of that compounded drug product in a calendar month. It's an enforcement position aimed at 503A compounders. It isn't approval, and it doesn't mean every other requirement is satisfied.

Does adding B12 make a compounded GLP-1 allowed? Not by itself. The FDA published an example showing that a semaglutide-plus-B12 injection can still be essentially a copy when the amounts of each ingredient fall within 10% of the strengths of the respective commercially available products and it's taken the same way.

Are semaglutide sodium and semaglutide acetate the same as what's in Ozempic? No. The FDA says these salt forms are different active ingredients than the ones in the approved drugs, that it doesn't have information on whether they behave the same way, and that it isn't aware of any lawful basis for using them in compounding. Treat them as a stop sign.

Can I buy retatrutide or cagrilintide instead? No. The FDA states these cannot be used in compounding under federal law, aren't components of FDA-approved drugs, and haven't been found safe and effective for any condition.

Is the 2026 503B Bulks List proposal final? Not as of August 20, 2026. The FDA proposed in April 2026 not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List. The comment period was extended and closed July 30, 2026. We searched for a final determination and didn't find one. Even a final non-inclusion would leave the separate shortage-list route in the statute.

Am I breaking the law by taking a compounded GLP-1? The FDA actions discussed here target the companies involved, not patients. The warning letters we reviewed went to companies. Don't stop or change your medication because of an article — talk to your prescriber.

Could compounding come back if there's another shortage? Shortage status can change, and it changes the analysis. The pending 503B proposal could finalize non-inclusion on the Bulks List, but it would not erase the separate shortage-list route. Planning your treatment around a future shortage still isn't a plan. Work with what's available today.

Why do I still see compounded GLP-1s advertised everywhere? An ad doesn't prove that a product fits a narrow legal lane. Some offers may fit the rules; some may not. The FDA's enforcement has focused heavily on how these products are marketed. Verify the prescriber, the pharmacy, and the stated basis before you trust the ad.

---

What we actually verified

On August 20, 2026, we opened and read:

• The FDA's compounding policy page and October 17, 2024 tirzepatide letter — the reevaluation policy, every later wind-down date, and the four-or-fewer policy
• The FDA's 503A copy guidance and 503B copy guidance — the different copy, patient-difference, and bulk-ingredient tests
• The FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — adverse event counts, salt forms, red flags, dosing errors, and storage
• The FDA Drug Shortages Database — liraglutide status, package by package, with each row's own update date
• FDA Warning Letters to Ready Med and Boothwyn Pharmacy — read in full
• The Federal Register proposal and deadline extension
• FDA Pharmacy Compounding Advisory Committee materials from July 23–24, 2026
• The Fifth Circuit's opinion database and oral-argument records for Nos. 25-10600 and 25-10758
• FDA labels for Wegovy, Zepbound, and Foundayo
• Official pricing and program pages from NovoCare, LillyDirect, CMS, Ro, and Sesame
• The live How Find My Path Works page
• The NABP board directory used to route readers to state pharmacy regulators
• The 2026 tirzepatide/B12 paper's PubMed record

What we looked for and did not find: a final Federal Register determination on the 503B Bulks List proposal, and a Fifth Circuit opinion in either OFA v. FDA appeal. Both were still unresolved when we checked. Either could change parts of this page.

What needs re-checking before you act: any price, discount, formulary result, and eligibility decision. Medication pricing in this category changes quickly and offers expire. Confirm on the official page and at checkout.

Corrections: if you find something wrong here, tell us and we'll fix it with a dated note. That's our whole model.

---

Still not sure which GLP-1 program is right for you?

Take our free matching quiz. It asks up to nine plain-English questions about medication preference, health flags, payment path, state, and timing, then gives you a treatment and access route to discuss with a licensed clinician. No signup.

→ Take the free matching quiz

---

For clinics and pharmacies: the rules point one direction. The shortage and wind-down basis for routine semaglutide and tirzepatide copies is over under current facts, and the April 2026 proposal could finalize their non-inclusion on the separate 503B Bulks List. For 503A, treat any "significant difference" finding as genuinely individualized and documented — not a template applied across a patient panel. Don't use that 503A wording to answer a 503B question. The Ready Med letter shows the marketing exposure runs alongside the compounding exposure, and it reaches telehealth companies that never touched a compounding hood.

---

Sources

1. FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current April 1, 2026)
2. FDA — October 17, 2024 letter on tirzepatide reevaluation enforcement
3. FDA — 503A guidance: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product
4. FDA — 503B guidance: Compounded Drug Products That Are Essentially Copies of Approved Drug Products
5. FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current June 15, 2026)
6. FDA — Drug Shortages Database, liraglutide injection data pulled August 20, 2026
7. FDA — Warning Letter to Ready Med, MARCS-CMS 730317 (June 8, 2026)
8. FDA — Warning Letter to Boothwyn Pharmacy LLC, MARCS-CMS 717525 (January 16, 2026)
9. FDA — FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (March 3, 2026)
10. Federal Register — 91 FR 23431 (May 1, 2026) and comment-period extension (June 26, 2026)
11. FDA — Pharmacy Compounding Advisory Committee meeting materials (July 23–24, 2026)
12. Outsourcing Facilities Association v. FDA, district cases 4:24-cv-00953 and 4:25-cv-00174; Fifth Circuit Nos. 25-10600 and 25-10758
13. CMS — Medicare GLP-1 Bridge
14. Novo Nordisk — NovoCare Wegovy savings and self-pay pricing; FDA Wegovy prescribing information
15. Eli Lilly — LillyDirect Zepbound pricing, Zepbound prescribing information, LillyDirect Foundayo pricing, and Foundayo prescribing information
16. Ro — Weight Loss Program Pricing, Insurance, and GLP-1 Insurance Coverage Checker
17. Sesame — online weight-loss program and Costco program update
18. The RX Index — How Find My Path Works
19. National Association of Boards of Pharmacy — Boards of Pharmacy directory
20. Yao et al. — A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications, Expert Opinion on Drug Safety (2026)

Content is for general information and is not medical or legal advice. Talk to a licensed clinician before changing any medication. A qualified lawyer can advise on a specific pharmacy, prescription, business model, or state-law question.

Related reading

• Is compounded GLP-1 still available in 2026?
• Compounded GLP-1 enforcement tracker
• GLP-1 lawsuits and enforcement tracker
• What does the 503B Bulks List mean for patients?
• Compounded vs. FDA-approved GLP-1s
• GLP-1 cost without insurance

---